<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03469674</url>
  </required_header>
  <id_info>
    <org_study_id>P16.054</org_study_id>
    <secondary_id>UL2011-5336</secondary_id>
    <secondary_id>ISRCTN11659025</secondary_id>
    <secondary_id>NTR5841</secondary_id>
    <nct_id>NCT03469674</nct_id>
  </id_info>
  <brief_title>PORTEC-4a: Molecular Profile-based Versus Standard Adjuvant Radiotherapy in Endometrial Cancer</brief_title>
  <acronym>PORTEC-4a</acronym>
  <official_title>Randomised Phase III Trial of Molecular Profile-based Versus Standard Recommendations for Adjuvant Radiotherapy for Women With Early Stage Endometrial Cancer: PORTEC-4a Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Leiden University Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Dutch Cancer Society</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Comprehensive Cancer Centre The Netherlands</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Leiden University Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is prospective, multicenter, randomised phase III trial among women with endometrial
      cancer with high-intermediate risk features to investigate the role of an integrated
      clinicopathological and molecular risk profile to determine if participants should receive no
      adjuvant therapy, vaginal brachytherapy or external beam radiotherapy based on a favourable,
      intermediate or unfavourable profile as compared to standard adjuvant vaginal brachytherapy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Adjuvant therapy for women with endometrial cancer has increasingly been tailored to
      prognostic factors to prevent overtreatment and select those women for adjuvant treatment who
      will have a clinically relevant reduction of the risk of relapse by the adjuvant treatment.
      Risk profiles have traditionally been based on clinicopathological factors such as age,
      stage, grade, LVSI and depth of invasion. Newer, both molecular-genetic (the cancer genome
      atlas subgroups) or immunohistochemistry-based (L1-CAM) risk factors have become available
      which are strongly related to outcomes and risk of cancer spread. In a comprehensive analysis
      of the PORTEC-1 and-2 biobank an integrated clinicopathological and molecular risk profile
      was determined which separated the current high-intermediate risk group of endometrial cancer
      in 3 separate groups (favourable, intermediate or unfavourable) with clearly separated
      outcomes, which is now prospectively tested in the clinic to determine adjuvant treatment.
      This is the first randomised trial using the molecular risk factors to assign adjuvant
      treatment for women with stage I-II high-intermediate risk endometrial cancer.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 10, 2016</start_date>
  <completion_date type="Anticipated">December 2028</completion_date>
  <primary_completion_date type="Anticipated">December 2026</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>2:1 randomisation to adjuvant treatment assignment based on the integrated molecular risk profile or standard adjuvant vaginal brachytherapy</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
    <masking_description>Evaluation of outcomes is done without information on randomised arm</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Vaginal recurrence</measure>
    <time_frame>5 years</time_frame>
    <description>Total vaginal recurrence and vaginal recurrence as first failure</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adverse events</measure>
    <time_frame>5 years</time_frame>
    <description>Treatment-related symptoms according to CTCAE v 4.0</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health-related cancer-specific quality of life</measure>
    <time_frame>5 years</time_frame>
    <description>Cancer-specific quality of life (European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Core Questionnaire (QLQC-30) - clinically relevant changes on QLQC30 functioning scales, general quality of life and general cancer symptoms</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Endometrial cancer-related symptoms and quality of life</measure>
    <time_frame>5 years</time_frame>
    <description>Endometrial cancer-related specific symptoms (EORTC EN24 module)- clinically relevant changes on these scales (quite a bit/very much vs no or mild symptoms)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relapse-free survival</measure>
    <time_frame>5 years</time_frame>
    <description>Relapse-free survival (survival without relapse)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Survival</measure>
    <time_frame>5 years</time_frame>
    <description>Overall survival (all-cause death)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>5-year vaginal control including treatment for relapse</measure>
    <time_frame>5 years</time_frame>
    <description>Long-term local control including salvage treatment for local relapse</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pelvic recurrence (total)</measure>
    <time_frame>5 years</time_frame>
    <description>Total pelvic recurrences</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pelvic recurrence as first failure</measure>
    <time_frame>5 years</time_frame>
    <description>Pelvic recurrence as first failure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Distant recurrence (total)</measure>
    <time_frame>5 years</time_frame>
    <description>Total distant recurrences</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Distant recurrence as first failure</measure>
    <time_frame>5 years</time_frame>
    <description>Distant recurrence as first failure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Endometrial cancer related health care costs</measure>
    <time_frame>5 years</time_frame>
    <description>All hospital based health care costs used with primary treatment or during followup for treatment of adverse events and/or treatment for relapse</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Recurrence (vaginal and total) per risk profile</measure>
    <time_frame>5 years</time_frame>
    <description>Vaginal, pelvic and distant relapse split by risk profile and compared between the 2 arms</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">500</enrollment>
  <condition>Endometrial Cancer Stage I</condition>
  <condition>Endometrial Cancer Stage II</condition>
  <arm_group>
    <arm_group_label>Molecular profile based treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Determination of the integrated clinicopathological and molecular profile to determine adjuvant treatment: observation for favourable profile; vaginal brachytherapy for intermediate profile; external beam radiotherapy for unfavourable profile</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vaginal brachytherapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Adjuvant vaginal brachytherapy (standard treatment)</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Vaginal brachytherapy</intervention_name>
    <description>Internal radiation of the vaginal vault using a vaginal cylinder, 21 Gy in 3 out-patient sessions over 2 weeks</description>
    <arm_group_label>Molecular profile based treatment</arm_group_label>
    <arm_group_label>Vaginal brachytherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>External beam radiotherapy</intervention_name>
    <description>External beam pelvic radiotherapy on a linear accelerator, 48.6 Gy in 27 out-patients sessions over 5.5 weeks</description>
    <arm_group_label>Molecular profile based treatment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Observation</intervention_name>
    <description>No radiation therapy, but active follow-up and quality of life questionnaires as in the groups who have adjuvant treatment</description>
    <arm_group_label>Molecular profile based treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically confirmed endometrioid type endometrial carcinoma, International
             Federation of Gynecology and Obstetrics (FIGO) 2009 stage I, with one of the following
             combinations of stage, grade, age, and lymph-vascular space invasion (LVSI):

               1. Stage IA, grade 3 (any age, with or without LVSI)

               2. Stage IB, grade 1 or 2 and age &gt;60 years

               3. Stage IB, grade 1-2 with documented LVSI

               4. Stage IB, grade 3 without LVSI

               5. Stage II (microscopic), grade 1

          -  World Health Organization (WHO)-performance status 0-2

          -  Written informed consent

        Exclusion Criteria:

          -  Any other stage and type of endometrial carcinoma

          -  Histological types serous carcinoma or clear cell carcinoma (at least 10% if mixed
             type), or undifferentiated or neuroendocrine carcinoma

          -  Uterine sarcoma (including carcinosarcoma)

          -  Previous malignancy (except for non-melanomatous skin cancer) &lt; 5 yrs

          -  Previous pelvic radiotherapy

          -  Interval between the operation and start of radiotherapy exceeding 8 weeks
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Carien L. Creutzberg, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Leiden University Medical Center, Dept of Radiation Oncology</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Remi Nout, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>ErasmusMC Dept of Radiation Oncology</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Chief Investigator</last_name>
    <phone>+3165263057</phone>
    <email>c.l.creutzberg@lumc.nl</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Karen Verhoeven-Adema, PhD</last_name>
    <phone>+3188 234 6125</phone>
    <email>portec@iknl.nl</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University Hospital Gent</name>
      <address>
        <city>Gent</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Katrien Vandecasteele, MD, PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CEEGOG, General Faculty Hospital and First Faculty of Medicine, Charles University, Prague</name>
      <address>
        <city>Praha</city>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Simona Skácelová</last_name>
    </contact>
    <investigator>
      <last_name>David Cibula, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>GINECO</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Enrolling by invitation</status>
  </location>
  <location>
    <facility>
      <name>Evang. Kliniken Essen-Mitte</name>
      <address>
        <city>Essen</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Beyhan Ataseven, MD, PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Rotkreuzklinikum München</name>
      <address>
        <city>Münich</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Harry Reisch, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospital</name>
      <address>
        <city>Tübingen</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stefan Kommoss, MD, PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CancerTrials Ireland - St James Hospital (SLRON SJH)</name>
      <address>
        <city>Dublin</city>
        <country>Ireland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Charles Gilham, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CancerTrials Ireland - St Luke's Hospital (SLRON SLH)</name>
      <address>
        <city>Dublin</city>
        <country>Ireland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Charles GIlham, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Academic Medical Center</name>
      <address>
        <city>Amsterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Henrike Westerveld, MDd PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>NKI / Antoni van Leeuwenhoekhuis</name>
      <address>
        <city>Amsterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marlies Nowee, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Radiation Therapy Group</name>
      <address>
        <city>Arnhem</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dorien Haverkort, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Haaglanden Medical Center</name>
      <address>
        <city>Den Haag</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tanja Stam</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Catharina Hospital</name>
      <address>
        <city>Eindhoven</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hetty van den Berg, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Medical Center Groningen</name>
      <address>
        <city>Groningen</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stefan Bijmolt, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Radiotherapy Institute Friesland</name>
      <address>
        <city>Leeuwarden</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Annerie Slot, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Leiden University Medical Center</name>
      <address>
        <city>Leiden</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Corine de Jong</last_name>
    </contact>
    <investigator>
      <last_name>Carien Creutzberg</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>MAASTRO radiation oncology clinic</name>
      <address>
        <city>Maastricht</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ludy Lutgens, MD, PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Radboud University Medical Center</name>
      <address>
        <city>Nijmegen</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>An Snyers, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>ErasmusMC Cancer Center</name>
      <address>
        <city>Rotterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jan Willem Mens</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Verbeeten institute</name>
      <address>
        <city>Tilburg</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Friederike Koppe, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Medical Center Utrecht</name>
      <address>
        <city>Utrecht</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ina Jürgenliemk-Schulz, MD, PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Zuidwest Radiotherapy Institute</name>
      <address>
        <city>Vlissingen</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Veronique Coen, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Isala Clinics</name>
      <address>
        <city>Zwolle</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lida Zwanenburg, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Czechia</country>
    <country>France</country>
    <country>Germany</country>
    <country>Ireland</country>
    <country>Netherlands</country>
  </location_countries>
  <link>
    <url>http://www.msbi.nl/portec4</url>
    <description>Study website</description>
  </link>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>March 8, 2018</study_first_submitted>
  <study_first_submitted_qc>March 16, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">March 19, 2018</study_first_posted>
  <last_update_submitted>February 9, 2020</last_update_submitted>
  <last_update_submitted_qc>February 9, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 11, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Leiden University Medical Center</investigator_affiliation>
    <investigator_full_name>Carien Creutzberg</investigator_full_name>
    <investigator_title>Chief Investigator</investigator_title>
  </responsible_party>
  <keyword>Radiotherapy</keyword>
  <keyword>Vaginal brachytherapy</keyword>
  <keyword>Molecular risk factors</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Endometrial Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Specifics will be decided and made public on website at a later stage, most probably from 5 years after final publication onwards</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>From 5 years after final publication onwards</ipd_time_frame>
    <ipd_access_criteria>Upon written application with a clear decription of aim, methods and analysis plan, publication plan, after approval from the study team</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

